Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6992168 | 0.92 | HSD17B10 (0.38) | L3MBTL1MAPK1HSD17B10USP2GAA | |
| SCHEMBL6998255 | 0.84 | PARP1 (0.45) | L3MBTL1 | |
| SCHEMBL7711370 | 0.77 | L3MBTL1 (0.37) | L3MBTL1MAPK1BRD4HSD17B10USP2 | |
| SCHEMBL6991112 | 0.73 | PARP1 (0.53) | L3MBTL1MAPK1BRD4HSD17B10USP2 | |
| SCHEMBL6991119 | 0.71 | MAPK1 (0.42) | L3MBTL1MAPK1BRD4HSD17B10USP2 | |
| SCHEMBL7713262 | 0.69 | USP2 (0.37) | L3MBTL1HSD17B10USP2GAATP53 | |
| SCHEMBL4821188 | 0.69 | PARP1 (0.58) | L3MBTL1MAPK1BRD4HSD17B10USP2 | |
| SCHEMBL6999246 | 0.68 | PARP1 (0.48) | USP2GAA | |
| SCHEMBL2163564 | 0.67 | L3MBTL1 (0.51) | L3MBTL1MAPK1BRD4HSD17B10USP2 | |
| SCHEMBL7711398 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1015437-B1 | BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS | SCHERING AG (DE) | 2003-12-03 | — | — | EP | disclosed |
| US-6365736-B1 | TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-04-02 | — | — | US | disclosed |